{"text": "Carrier-free radioiodinated << [125I]IAS >> was used to photolabel epitope-tagged [[ human beta 2AR ]] in membranes prepared from stably transfected HEK 293 cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "Probing the salmeterol binding site on the << beta 2-adrenergic receptor >> using a novel photoaffinity ligand, [[ [(125)I]iodoazidosalmeterol ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "Probing the << salmeterol >> binding site on the [[ beta 2-adrenergic receptor ]] using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "<< Salmeterol >> is a long-acting [[ beta2-adrenergic receptor ]] (beta 2AR) agonist used clinically to treat asthma.", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "<< Salmeterol >> is a long-acting beta2-adrenergic receptor ([[ beta 2AR ]]) agonist used clinically to treat asthma.", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "To determine the position of the phenyl ring of the aralkyloxyalkyl side chain of << salmeterol >> in the [[ beta 2AR ]] binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([125I]IAS).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "To determine the position of the phenyl ring of the << aralkyloxyalkyl >> side chain of salmeterol in the [[ beta 2AR ]] binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([125I]IAS).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "To determine the position of the << phenyl >> ring of the aralkyloxyalkyl side chain of salmeterol in the [[ beta 2AR ]] binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([125I]IAS).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "To determine the position of the phenyl ring of the aralkyloxyalkyl side chain of salmeterol in the << beta 2AR >> binding site, we designed and synthesized the agonist photoaffinity label [[ [(125)I]iodoazidosalmeterol ]] ([125I]IAS).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "To determine the position of the phenyl ring of the aralkyloxyalkyl side chain of salmeterol in the << beta 2AR >> binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([[ [125I]IAS ]]).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "In direct << adenylyl cyclase >> activation, in effects on adenylyl cyclase after pretreatment of intact cells, and in guinea pig tracheal relaxation assays, [[ IAS ]] and the parent drug salmeterol behave essentially the same.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "In direct << adenylyl cyclase >> activation, in effects on adenylyl cyclase after pretreatment of intact cells, and in guinea pig tracheal relaxation assays, IAS and the parent drug [[ salmeterol ]] behave essentially the same.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "In direct adenylyl cyclase activation, in effects on << adenylyl cyclase >> after pretreatment of intact cells, and in guinea pig tracheal relaxation assays, [[ IAS ]] and the parent drug salmeterol behave essentially the same.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "In direct adenylyl cyclase activation, in effects on << adenylyl cyclase >> after pretreatment of intact cells, and in guinea pig tracheal relaxation assays, IAS and the parent drug [[ salmeterol ]] behave essentially the same.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Labeling with [(125)I]IAS was blocked by 10 microM (-)-alprenolol and inhibited by addition of GTP gamma S, and [125I]IAS migrated at the same position on an SDS-PAGE gel as the << beta 2AR >> labeled by the antagonist photoaffinity label [[ [125I]iodoazidobenzylpindolol ]] ([125I]IABP).", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "Labeling with [(125)I]IAS was blocked by 10 microM (-)-alprenolol and inhibited by addition of GTP gamma S, and [125I]IAS migrated at the same position on an SDS-PAGE gel as the << beta 2AR >> labeled by the antagonist photoaffinity label [125I]iodoazidobenzylpindolol ([[ [125I]IABP ]]).", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "Labeling with [(125)I]IAS was blocked by 10 microM (-)-alprenolol and inhibited by addition of GTP gamma S, and << [125I]IAS >> migrated at the same position on an SDS-PAGE gel as the [[ beta 2AR ]] labeled by the antagonist photoaffinity label [125I]iodoazidobenzylpindolol ([125I]IABP).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "Labeling with << [(125)I]IAS >> was blocked by 10 microM (-)-alprenolol and inhibited by addition of GTP gamma S, and [125I]IAS migrated at the same position on an SDS-PAGE gel as the [[ beta 2AR ]] labeled by the antagonist photoaffinity label [125I]iodoazidobenzylpindolol ([125I]IABP).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "A model of << IAS >> binding to the [[ beta 2AR ]] is proposed.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "Labeling with [(125)I]IAS was blocked by 10 microM << (-)-alprenolol >> and inhibited by addition of GTP gamma S, and [125I]IAS migrated at the same position on an SDS-PAGE gel as the [[ beta 2AR ]] labeled by the antagonist photoaffinity label [125I]iodoazidobenzylpindolol ([125I]IABP).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "<< Apomorphine >> is a bimodal modulator of [[ TRPA1 ]] channels.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Here, we show that << rTRPV1 >>, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward [[ apomorphine ]] treatment.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "Here, we show that rTRPV1, << rTRPV2 >>, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward [[ apomorphine ]] treatment.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "Here, we show that rTRPV1, rTRPV2, << rTRPV3 >>, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward [[ apomorphine ]] treatment.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "Here, we show that rTRPV1, rTRPV2, rTRPV3, and << mTRPV4 >>, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward [[ apomorphine ]] treatment.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as << hTRPM8 >>, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward [[ apomorphine ]] treatment.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and << rTRPM3 >>, which are expressed in dorsal root ganglion neurons, are insensitive toward [[ apomorphine ]] treatment.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "On the contrary, << human TRPA1 >> could be concentration-dependently modulated by [[ apomorphine ]].", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Whereas the addition of << apomorphine >> in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [[ TRPA1 ]] channels, resulting from a reduction of single-channel open times.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "In addition, we provide evidence that << apomorphine >> also acts on endogenous [[ TRPA1 ]] in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of TRPA1.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "In addition, we provide evidence that << apomorphine >> also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of [[ TRPA1 ]].", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Our study shows that << human TRPA1 >> is a target for [[ apomorphine ]], suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Our study shows that human TRPA1 is a target for << apomorphine >>, suggesting that an activation of [[ TRPA1 ]] might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Our study shows that << human TRPA1 >> is a target for apomorphine, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with [[ apomorphine ]].", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of << TRPA1 >> might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with [[ apomorphine ]].", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Whereas the addition of << apomorphine >> in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [[ TRPA1 ]] channels, resulting from a reduction of single-channel open times.", "metadata": [], "label": "ACTIVATOR", "cpr": "3"}
{"text": "<< Vitamin C >> forestalls cigarette smoke induced [[ NF-κB ]] activation in alveolar epithelial cells.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "It is possible that << vitamin C >>, an antioxidant, may prevent cigarette smoke (CS)-induced [[ NF-κB ]] activation that involves degradation of I-κBε and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "It is possible that << vitamin C >>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of [[ I-κBε ]] and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "It is possible that << vitamin C >>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of I-κBε and nuclear translocation of [[ c-Rel ]]/p50 in alveolar epithelial cells.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "It is possible that << vitamin C >>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of I-κBε and nuclear translocation of c-Rel/[[ p50 ]] in alveolar epithelial cells.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "We observed a significant reduction in CSE induced luciferase expression, << NF-κB >> DNA binding, I-κBε degradation and c-Rel nuclear translocation in cells pretreated with [[ vitamin C ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "We observed a significant reduction in CSE induced luciferase expression, NF-κB DNA binding, << I-κBε >> degradation and c-Rel nuclear translocation in cells pretreated with [[ vitamin C ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "We observed a significant reduction in CSE induced luciferase expression, NF-κB DNA binding, I-κBε degradation and << c-Rel >> nuclear translocation in cells pretreated with [[ vitamin C ]].", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "We observed a significant reduction in CSE induced luciferase expression, NF-κB DNA binding, I-κBε degradation and c-Rel nuclear translocation in cells pretreated with vitamin C. To further validate the result, we examined sub-cellular distribution of c-Rel in lungs of CS-exposed guinea pigs treated or untreated with vitamin C. Result showed that << vitamin C >> treatment resulted in markedly reduced [[ c-Rel ]] nuclear translocation.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "All these results demonstrate that << vitamin C >> prevents CS(E)-induced [[ NF-κB ]] activation and thus it could be used for the prevention of CS-induced inflammatory diseases.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "In comparison to homozygous, wild type (WT) mice, HZ mice show a 40% reduction of AChE activity in the brain, while their hippocampal ACh levels are increased by 56% as measured by microdialysis; << choline acetyltransferase >> levels remain unaltered, and [[ choline ]] uptake increases 2-fold.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "We demonstrate that HZ mice are significantly more sensitive to local << AChE >> inhibition ([[ BW284c51 ]]), but remain insensitive to butyrylcholinesterase (BuChE) inhibition (bambuterol).", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "We demonstrate that HZ mice are significantly more sensitive to local AChE inhibition (BW284c51), but remain insensitive to << butyrylcholinesterase >> (BuChE) inhibition ([[ bambuterol ]]).", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "We demonstrate that HZ mice are significantly more sensitive to local AChE inhibition (BW284c51), but remain insensitive to butyrylcholinesterase (<< BuChE >>) inhibition ([[ bambuterol ]]).", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "HZ mice are also more sensitive to the peripheral application of the selective << AChE >> inhibitor [[ donepezil ]] or the mixed inhibitor physostigmine; extracellular ACh levels rise significantly after administration of both drugs; also glucose levels are moderately increased indicating potentially non-cholinergic effects of donepezil.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "HZ mice are also more sensitive to the peripheral application of the selective << AChE >> inhibitor donepezil or the mixed inhibitor physostigmine; extracellular ACh levels rise significantly after administration of both drugs; also glucose levels are moderately increased indicating potentially non-cholinergic effects of [[ donepezil ]].", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "HZ mice are also more sensitive to the peripheral application of the selective << AChE >> inhibitor donepezil or the mixed inhibitor [[ physostigmine ]]; extracellular ACh levels rise significantly after administration of both drugs; also glucose levels are moderately increased indicating potentially non-cholinergic effects of donepezil.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "HZ mice are also more sensitive to the peripheral application of the selective << AChE >> inhibitor donepezil or the mixed inhibitor physostigmine; extracellular [[ ACh ]] levels rise significantly after administration of both drugs; also glucose levels are moderately increased indicating potentially non-cholinergic effects of donepezil.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Sustained resistance to acute << MPTP >> toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of [[ parkin ]] protein.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant << 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine >> (MPTP), and the resistance of TIDA neurons to MPTP is associated with increased expression of [[ parkin ]] and ubiquitin carboxy-terminal hydrolase L-1 (UCHL- 1).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (<< MPTP >>), and the resistance of TIDA neurons to MPTP is associated with increased expression of [[ parkin ]] and ubiquitin carboxy-terminal hydrolase L-1 (UCHL- 1).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and the resistance of TIDA neurons to << MPTP >> is associated with increased expression of [[ parkin ]] and ubiquitin carboxy-terminal hydrolase L-1 (UCHL- 1).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant << 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine >> (MPTP), and the resistance of TIDA neurons to MPTP is associated with increased expression of parkin and [[ ubiquitin carboxy-terminal hydrolase L-1 ]] (UCHL- 1).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (<< MPTP >>), and the resistance of TIDA neurons to MPTP is associated with increased expression of parkin and [[ ubiquitin carboxy-terminal hydrolase L-1 ]] (UCHL- 1).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and the resistance of TIDA neurons to << MPTP >> is associated with increased expression of parkin and [[ ubiquitin carboxy-terminal hydrolase L-1 ]] (UCHL- 1).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant << 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine >> (MPTP), and the resistance of TIDA neurons to MPTP is associated with increased expression of parkin and ubiquitin carboxy-terminal hydrolase L-1 ([[ UCHL- 1 ]]).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (<< MPTP >>), and the resistance of TIDA neurons to MPTP is associated with increased expression of parkin and ubiquitin carboxy-terminal hydrolase L-1 ([[ UCHL- 1 ]]).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and the resistance of TIDA neurons to << MPTP >> is associated with increased expression of parkin and ubiquitin carboxy-terminal hydrolase L-1 ([[ UCHL- 1 ]]).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, << tyrosine hydroxylase >> (TH) and DA transporter concentrations in the striatum) as well as loss of TH-immunoreactive (IR) neurons in the substantia nigra (SN) following [[ MPTP ]], whereas TIDA neurons revealed no overt axon terminal pathology or loss of TH-IR cell bodies.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, tyrosine hydroxylase (<< TH >>) and DA transporter concentrations in the striatum) as well as loss of TH-immunoreactive (IR) neurons in the substantia nigra (SN) following [[ MPTP ]], whereas TIDA neurons revealed no overt axon terminal pathology or loss of TH-IR cell bodies.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, tyrosine hydroxylase (TH) and << DA transporter >> concentrations in the striatum) as well as loss of TH-immunoreactive (IR) neurons in the substantia nigra (SN) following [[ MPTP ]], whereas TIDA neurons revealed no overt axon terminal pathology or loss of TH-IR cell bodies.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, tyrosine hydroxylase (TH) and DA transporter concentrations in the striatum) as well as loss of << TH >>-immunoreactive (IR) neurons in the substantia nigra (SN) following [[ MPTP ]], whereas TIDA neurons revealed no overt axon terminal pathology or loss of TH-IR cell bodies.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "Resistance of TIDA neurons to << MPTP >> toxicity was correlated with a transient increase in [[ UCHL-1 ]] and a sustained elevation in parkin in the arcuate nucleus.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Resistance of TIDA neurons to << MPTP >> toxicity was correlated with a transient increase in UCHL-1 and a sustained elevation in [[ parkin ]] in the arcuate nucleus.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, tyrosine hydroxylase (TH) and DA transporter concentrations in the striatum) as well as loss of TH-immunoreactive (IR) neurons in the substantia nigra (SN) following << MPTP >>, whereas TIDA neurons revealed no overt axon terminal pathology or loss of [[ TH ]]-IR cell bodies.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "BACKGROUND: << Norepinephrine transporter >> (NET) is involved in the regulation of [[ norepinephrine ]] (NE) turnover and metabolism.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "BACKGROUND: Norepinephrine transporter (<< NET >>) is involved in the regulation of [[ norepinephrine ]] (NE) turnover and metabolism.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "BACKGROUND: Norepinephrine transporter (<< NET >>) is involved in the regulation of norepinephrine ([[ NE ]]) turnover and metabolism.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "BACKGROUND: << Norepinephrine transporter >> (NET) is involved in the regulation of norepinephrine ([[ NE ]]) turnover and metabolism.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Neuronal << NE >> reuptake may be impaired in individuals with renal disease and/or hypertension due to dysfunction of the [[ NE transporter ]].", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Accumulation of << glutathione disulfide >> mediates [[ NF-kappaB ]] activation during immune stimulation with CpG DNA.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Treatment of cells with << BCNU >> to inhibit [[ glutathione reductase ]] (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and TNF-alpha.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Treatment of cells with << BCNU >> to inhibit glutathione reductase ([[ GR ]]) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and TNF-alpha.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Treatment of cells with << BCNU >> to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of [[ NF-kappaB ]] and a doubling in the CpG-induced production of IL-6 and TNF-alpha.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Treatment of cells with << BCNU >> to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of [[ IL-6 ]] and TNF-alpha.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Treatment of cells with << BCNU >> to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and [[ TNF-alpha ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Experimental manipulation of the intracellular GSSG concentration during inhibition of cellular prooxidant production demonstrated that increased intracellular << GSSG >> is a primary signal that is directly or indirectly required for CpG-induced [[ NF-kappaB ]] activation but is not in itself sufficient to trigger this in the absence of CpG ODN.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Experimental manipulation of the intracellular << GSSG >> concentration during inhibition of cellular prooxidant production demonstrated that increased intracellular GSSG is a primary signal that is directly or indirectly required for CpG-induced [[ NF-kappaB ]] activation but is not in itself sufficient to trigger this in the absence of CpG ODN.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the << GSH >>/GSSG, with increased activation of [[ NF-kappaB ]] and a doubling in the CpG-induced production of IL-6 and TNF-alpha.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the << GSH >>/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of [[ IL-6 ]] and TNF-alpha.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the << GSH >>/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and [[ TNF-alpha ]].", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/<< GSSG >>, with increased activation of [[ NF-kappaB ]] and a doubling in the CpG-induced production of IL-6 and TNF-alpha.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/<< GSSG >>, with increased activation of NF-kappaB and a doubling in the CpG-induced production of [[ IL-6 ]] and TNF-alpha.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/<< GSSG >>, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and [[ TNF-alpha ]].", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "RESULTS: After treatment with << triflusal >>, there was an increase in NO production by neutrophils and an increase in [[ endothelial nitric oxide synthase ]] (eNOS) protein expression in neutrophils.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "RESULTS: After treatment with << triflusal >>, there was an increase in NO production by neutrophils and an increase in endothelial nitric oxide synthase ([[ eNOS ]]) protein expression in neutrophils.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "A slight decrease in << P-selectin >> surface expression on platelets was found which was not modified by the presence of neutrophils and therefore by the neutrophil-derived [[ NO ]].", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "CONCLUSION: Oral treatment of healthy volunteers with << triflusal >> stimulated NO production and [[ eNOS ]] protein expression in their neutrophils.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "However, the neutrophils and the endogenous << NO >> generated by them failed to modify [[ P-selectin ]] expression in ADP-activated platelets.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "<< Methamphetamine >> increases the hippocampal [[ alpha(2A)-adrenergic receptor ]] and Galpha(o) in mice.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "<< Methamphetamine >> increases the hippocampal alpha(2A)-adrenergic receptor and [[ Galpha(o) ]] in mice.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "This study investigates the involvement of << alpha(2)-adrenergic receptors >> (AR) in mouse brain induced by a low dose of [[ methamphetamine ]] (METH, 2 mg/kg).", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "This study investigates the involvement of alpha(2)-adrenergic receptors (<< AR >>) in mouse brain induced by a low dose of [[ methamphetamine ]] (METH, 2 mg/kg).", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "This study investigates the involvement of << alpha(2)-adrenergic receptors >> (AR) in mouse brain induced by a low dose of methamphetamine ([[ METH ]], 2 mg/kg).", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "This study investigates the involvement of alpha(2)-adrenergic receptors (<< AR >>) in mouse brain induced by a low dose of methamphetamine ([[ METH ]], 2 mg/kg).", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Immunohistochemical studies show that << alpha(2A)-AR >> increased in the dentate gyrus area of the hippocampus 24 h after five repeated administrations of [[ METH ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "These suggest that the repeated administration of low-doses of << METH >> causes quantitative changes of the signaling of [[ alpha(2A)-AR ]] in the mouse hippocampus.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Mechanism of << iodide >>-dependent catalatic activity of [[ thyroid peroxidase ]] and lactoperoxidase.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Mechanism of << iodide >>-dependent catalatic activity of thyroid peroxidase and [[ lactoperoxidase ]].", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Mechanisms that have been proposed for << peroxidase >>-catalyzed iodination require the utilization of 1 mol of [[ H2O2 ]] for organic binding of 1 mol of iodide.", "metadata": [], "label": "COFACTOR", "cpr": "8"}
{"text": "Mechanisms that have been proposed for << peroxidase >>-catalyzed iodination require the utilization of 1 mol of H2O2 for organic binding of 1 mol of [[ iodide ]].", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "This was shown to be attributable to << catalase >>-like activity of these enzymes, resulting in unproductive cleavage of [[ H2O2 ]].", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "3) The inhibitory effects of the << thioureylene >> drugs, methimazole and carbimazole, on the iodide-dependent catalatic activity were very similar to those reported previously for [[ thyroid peroxidase ]]-catalyzed iodination.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "3) The inhibitory effects of the thioureylene drugs, << methimazole >> and carbimazole, on the iodide-dependent catalatic activity were very similar to those reported previously for [[ thyroid peroxidase ]]-catalyzed iodination.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "3) The inhibitory effects of the thioureylene drugs, methimazole and << carbimazole >>, on the iodide-dependent catalatic activity were very similar to those reported previously for [[ thyroid peroxidase ]]-catalyzed iodination.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "4) High concentrations of << I- >> inhibited the catalatic activity of [[ thyroid peroxidase ]] and lactoperoxidase in a manner similar to that described previously for peroxidase-catalyzed iodination.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "4) High concentrations of << I- >> inhibited the catalatic activity of thyroid peroxidase and [[ lactoperoxidase ]] in a manner similar to that described previously for peroxidase-catalyzed iodination.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "4) High concentrations of << I- >> inhibited the catalatic activity of thyroid peroxidase and lactoperoxidase in a manner similar to that described previously for [[ peroxidase ]]-catalyzed iodination.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "On the basis of these observations and other findings, we have proposed a scheme which offers a possible explanation for << iodide >>-dependent catalatic activity of [[ thyroid peroxidase ]] and lactoperoxidase.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "On the basis of these observations and other findings, we have proposed a scheme which offers a possible explanation for << iodide >>-dependent catalatic activity of thyroid peroxidase and [[ lactoperoxidase ]].", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Compound I of the peroxidases is represented as EO, and oxidation of I- by << EO >> is postulated to form enzyme-bound [[ hypoiodite ]], represented in our scheme as [EOI]-.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "Compound I of the peroxidases is represented as EO, and oxidation of I- by << EO >> is postulated to form enzyme-bound hypoiodite, represented in our scheme as [[[ EOI ]]]-.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "Compound I of the << peroxidases >> is represented as EO, and oxidation of I- by EO is postulated to form enzyme-bound [[ hypoiodite ]], represented in our scheme as [EOI]-.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "Compound I of the peroxidases is represented as << EO >>, and oxidation of I- by EO is postulated to form enzyme-bound [[ hypoiodite ]], represented in our scheme as [EOI]-.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "Compound I of the peroxidases is represented as << EO >>, and oxidation of I- by EO is postulated to form enzyme-bound hypoiodite, represented in our scheme as [[[ EOI ]]]-.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "Compound I of the << peroxidases >> is represented as EO, and oxidation of I- by EO is postulated to form enzyme-bound hypoiodite, represented in our scheme as [[[ EOI ]]]-.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "Compound I of the << peroxidases >> is represented as EO, and oxidation of [[ I- ]] by EO is postulated to form enzyme-bound hypoiodite, represented in our scheme as [EOI]-.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Compound I of the peroxidases is represented as << EO >>, and oxidation of [[ I- ]] by EO is postulated to form enzyme-bound hypoiodite, represented in our scheme as [EOI]-.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Compound I of the peroxidases is represented as EO, and oxidation of << I- >> by [[ EO ]] is postulated to form enzyme-bound hypoiodite, represented in our scheme as [EOI]-.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "We suggest that the latter can react with << H2O2 >> in a [[ catalase ]]-like reaction, with evolution of O2.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "We suggest that the latter can react with H2O2 in a << catalase >>-like reaction, with evolution of [[ O2 ]].", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide are secreted by enteroendocrine cells and augment << glucose >>-induced [[ insulin ]] secretion in response to food ingestion in a glucose-dependent manner.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide are secreted by enteroendocrine cells and augment glucose-induced << insulin >> secretion in response to food ingestion in a [[ glucose ]]-dependent manner.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg << dezocine >> from saline, a series of opioids with activity at the [[ mu opioid receptor ]] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the << mu opioid receptor >> substituted completely for the [[ dezocine ]] stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the << mu opioid receptor >> substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., [[ fentanyl ]] >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the << mu opioid receptor >> substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[[ [-]-cyclazocine ]] >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the << mu opioid receptor >> substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >[[ buprenorphine ]] = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the << mu opioid receptor >> substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = [[ butorphanol ]] >l-methadone >nalbuphine >[-]-metazocine >morphine).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the << mu opioid receptor >> substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >[[ l-methadone ]] >nalbuphine >[-]-metazocine >morphine).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the << mu opioid receptor >> substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >[[ nalbuphine ]] >[-]-metazocine >morphine).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the << mu opioid receptor >> substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[[ [-]-metazocine ]] >morphine).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the << mu opioid receptor >> substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >[[ morphine ]]).", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "Discriminative stimulus effects of the mixed-opioid agonist/antagonist << dezocine >>: cross-substitution by [[ mu and delta opioid ]] agonists.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The present findings indicate that << dezocine >> shares similar stimulus effects with both mu and delta agonists, its stimulus effects are reversed by mu-selective antagonists, and its rate-decreasing effects are not mediated by activity at [[ mu, kappa or delta opioid receptors ]].", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "The present findings indicate that << dezocine >> shares similar stimulus effects with both [[ mu and delta ]] agonists, its stimulus effects are reversed by mu-selective antagonists, and its rate-decreasing effects are not mediated by activity at mu, kappa or delta opioid receptors.", "metadata": [], "label": "AGONIST", "cpr": "5"}
{"text": "<< Ibandronate >> increases the expression of the pro-apoptotic gene [[ FAS ]] by epigenetic mechanisms in tumor cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Further we found stimulation of << FAS >>-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both [[ geranylgeranyl-pyrophosphate ]] and farnesylpyrophosphate.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of << DNMT1 >>, which was rescued by re-isoprenylation by both [[ geranylgeranyl-pyrophosphate ]] and farnesylpyrophosphate.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Further we found stimulation of << FAS >>-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and [[ farnesylpyrophosphate ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of << DNMT1 >>, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and [[ farnesylpyrophosphate ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "In contrast, << ibandronate >> did not affect [[ FAS ]] and DNMT1 expression in MC3T3-E1 non-neoplastic cells.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "In contrast, << ibandronate >> did not affect FAS and [[ DNMT1 ]] expression in MC3T3-E1 non-neoplastic cells.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "Data suggest that << bisphosphonates >> via modulation of the activity of small-[[ GTPases ]] induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS-expression.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Data suggest that << bisphosphonates >> via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of [[ FAS ]]-expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Sprague-Dawley rats treated with a non-selective cannabinoid agonist (<< CP55940 >>, 50μg/kg, 7 days, i.p.) showed enhanced co-immunoprecipitation of [[ β-Arrestin 2 ]] and ERK1/2, enhanced pERK protein levels, and enhanced expression of β-Arrestin 2 mRNA and protein levels in PFCx.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Sprague-Dawley rats treated with a non-selective cannabinoid agonist (<< CP55940 >>, 50μg/kg, 7 days, i.p.) showed enhanced co-immunoprecipitation of β-Arrestin 2 and [[ ERK1/2 ]], enhanced pERK protein levels, and enhanced expression of β-Arrestin 2 mRNA and protein levels in PFCx.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Sprague-Dawley rats treated with a non-selective cannabinoid agonist (<< CP55940 >>, 50μg/kg, 7 days, i.p.) showed enhanced co-immunoprecipitation of β-Arrestin 2 and ERK1/2, enhanced [[ pERK ]] protein levels, and enhanced expression of β-Arrestin 2 mRNA and protein levels in PFCx.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Sprague-Dawley rats treated with a non-selective cannabinoid agonist (<< CP55940 >>, 50μg/kg, 7 days, i.p.) showed enhanced co-immunoprecipitation of β-Arrestin 2 and ERK1/2, enhanced pERK protein levels, and enhanced expression of [[ β-Arrestin 2 ]] mRNA and protein levels in PFCx.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "In a neuronal cell line, we found that selective CB(2) receptor agonists upregulate β-Arrestin 2, an effect that was prevented by selective << CB(2) >> receptor antagonist [[ JTE-907 ]] and CB(2) shRNA lentiviral particles.", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "In a neuronal cell line, we found that selective << CB(2) >> receptor agonists upregulate β-Arrestin 2, an effect that was prevented by selective CB(2) receptor antagonist [[ JTE-907 ]] and CB(2) shRNA lentiviral particles.", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "In a neuronal cell line, we found that selective CB(2) receptor agonists upregulate β-Arrestin 2, an effect that was prevented by selective CB(2) receptor antagonist << JTE-907 >> and [[ CB(2) ]] shRNA lentiviral particles.", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "In a neuronal cell line, we found that selective CB(2) receptor agonists upregulate << β-Arrestin 2 >>, an effect that was prevented by selective CB(2) receptor antagonist [[ JTE-907 ]] and CB(2) shRNA lentiviral particles.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by << matrine >> and oxymatrine through up-regulating [[ transcription factor Sp1 ]] expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and << oxymatrine >> through up-regulating [[ transcription factor Sp1 ]] expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "<< Arsenic trioxide >>-induced [[ hERG ]] K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "<< Arsenic trioxide >>-induced hERG [[ K(+) channel ]] deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "Arsenic trioxide-induced << hERG >> K(+) channel deficiency can be rescued by [[ matrine ]] and oxymatrine through up-regulating transcription factor Sp1 expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Arsenic trioxide-induced hERG << K(+) channel >> deficiency can be rescued by [[ matrine ]] and oxymatrine through up-regulating transcription factor Sp1 expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Arsenic trioxide-induced << hERG >> K(+) channel deficiency can be rescued by matrine and [[ oxymatrine ]] through up-regulating transcription factor Sp1 expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Arsenic trioxide-induced hERG << K(+) channel >> deficiency can be rescued by matrine and [[ oxymatrine ]] through up-regulating transcription factor Sp1 expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "<< Arsenic trioxide >> (As(2)O(3)), which is used to treat acute promyelocytic leukemia, can cause LQTS type 2 (LQT2) by reducing the [[ hERG ]] current through the diversion of hERG trafficking to the cytoplasmic membrane.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "<< Arsenic trioxide >> (As(2)O(3)), which is used to treat acute promyelocytic leukemia, can cause LQTS type 2 (LQT2) by reducing the hERG current through the diversion of [[ hERG ]] trafficking to the cytoplasmic membrane.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "Arsenic trioxide (<< As(2)O(3) >>), which is used to treat acute promyelocytic leukemia, can cause LQTS type 2 (LQT2) by reducing the [[ hERG ]] current through the diversion of hERG trafficking to the cytoplasmic membrane.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "Arsenic trioxide (<< As(2)O(3) >>), which is used to treat acute promyelocytic leukemia, can cause LQTS type 2 (LQT2) by reducing the hERG current through the diversion of [[ hERG ]] trafficking to the cytoplasmic membrane.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "We reported that superfusion of << hERG >>-expressing HEK293 (hERG-HEK) cells with [[ matrine ]] (1, 10 μM) increased the hERG current by promoting hERG channel activation.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "We reported that superfusion of hERG-expressing HEK293 (<< hERG >>-HEK) cells with [[ matrine ]] (1, 10 μM) increased the hERG current by promoting hERG channel activation.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "We reported that superfusion of hERG-expressing HEK293 (hERG-HEK) cells with << matrine >> (1, 10 μM) increased the [[ hERG ]] current by promoting hERG channel activation.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "We reported that superfusion of hERG-expressing HEK293 (hERG-HEK) cells with << matrine >> (1, 10 μM) increased the hERG current by promoting [[ hERG ]] channel activation.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Long-term treatment with 1 μM << matrine >> or oxymatrine increased expression of the [[ hERG ]] protein and rescued the hERG surface expression disrupted by As(2)O(3).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Long-term treatment with 1 μM matrine or << oxymatrine >> increased expression of the [[ hERG ]] protein and rescued the hERG surface expression disrupted by As(2)O(3).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Long-term treatment with 1 μM << matrine >> or oxymatrine increased expression of the hERG protein and rescued the [[ hERG ]] surface expression disrupted by As(2)O(3).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Long-term treatment with 1 μM matrine or << oxymatrine >> increased expression of the hERG protein and rescued the [[ hERG ]] surface expression disrupted by As(2)O(3).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Long-term treatment with 1 μM matrine or oxymatrine increased expression of the hERG protein and rescued the << hERG >> surface expression disrupted by [[ As(2)O(3) ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "Long-term treatment with 1 μM matrine or oxymatrine increased expression of the << hERG >> protein and rescued the hERG surface expression disrupted by [[ As(2)O(3) ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "Therefore, matrine and << oxymatrine >> may have the potential to cure LQT2 as a potassium channel activator by promoting [[ hERG ]] channel activation and increasing hERG channel expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Therefore, << matrine >> and oxymatrine may have the potential to cure LQT2 as a potassium channel activator by promoting [[ hERG ]] channel activation and increasing hERG channel expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Therefore, << matrine >> and oxymatrine may have the potential to cure LQT2 as a potassium channel activator by promoting hERG channel activation and increasing [[ hERG ]] channel expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Therefore, matrine and << oxymatrine >> may have the potential to cure LQT2 as a potassium channel activator by promoting hERG channel activation and increasing [[ hERG ]] channel expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cpr": "3"}
{"text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the << dopamine D1 receptor >> antagonist [[ SCH 39166 ]] ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the << dopamine D1 receptor >> antagonist SCH 39166 ([[ (-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine ]]) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the << dopamine D2 receptor >> antagonist [[ raclopride ]] (both at 0.003-0.03 mg/kg).", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "Intracellular K+ is required for the inactivation-induced high-affinity binding of << cisapride >> to [[ HERG ]] channels.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "Intracellular << K+ >> is required for the inactivation-induced high-affinity binding of cisapride to [[ HERG ]] channels.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "In the present study, we examined the effect of inactivation gating on << cisapride >> block of [[ HERG ]].", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Modulation of << HERG >> inactivation was achieved by either changing extracellular [[ K+ ]] or Cs+ concentrations or by mutations of the channel.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Modulation of << HERG >> inactivation was achieved by either changing extracellular K+ or [[ Cs+ ]] concentrations or by mutations of the channel.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "We found that although inactivation facilitated << cisapride >> block of the [[ HERG ]] K+ current, it was not coupled with cisapride block of HERG when the Cs+ current was recorded.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "We found that although inactivation facilitated << cisapride >> block of the HERG K+ current, it was not coupled with cisapride block of [[ HERG ]] when the Cs+ current was recorded.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "We found that although inactivation facilitated cisapride block of the HERG K+ current, it was not coupled with << cisapride >> block of [[ HERG ]] when the Cs+ current was recorded.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "We found that although inactivation facilitated cisapride block of the << HERG >> K+ current, it was not coupled with [[ cisapride ]] block of HERG when the Cs+ current was recorded.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "We found that although inactivation facilitated cisapride block of the << HERG >> [[ K+ ]] current, it was not coupled with cisapride block of HERG when the Cs+ current was recorded.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "We found that although inactivation facilitated cisapride block of the HERG K+ current, it was not coupled with cisapride block of << HERG >> when the [[ Cs+ ]] current was recorded.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "We found that although inactivation facilitated cisapride block of the HERG << K+ >> current, it was not coupled with cisapride block of [[ HERG ]] when the Cs+ current was recorded.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "We found that although inactivation facilitated cisapride block of the << HERG >> K+ current, it was not coupled with cisapride block of HERG when the [[ Cs+ ]] current was recorded.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Furthermore, << cisapride >> block of the [[ HERG ]] K+ current was not linked with inactivation in the mutant HERG channels F656V and F656M.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Furthermore, cisapride block of the << HERG >> [[ K+ ]] current was not linked with inactivation in the mutant HERG channels F656V and F656M.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Furthermore, << cisapride >> block of the HERG K+ current was not linked with inactivation in the mutant [[ HERG ]] channels F656V and F656M.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Furthermore, cisapride block of the HERG << K+ >> current was not linked with inactivation in the mutant [[ HERG ]] channels F656V and F656M.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Our results suggest that inactivation facilitates << cisapride >> block of [[ HERG ]] channels through affecting the positioning of Phe-656.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Our results suggest that inactivation facilitates cisapride block of << HERG >> channels through affecting the positioning of [[ Phe ]]-656.", "metadata": [], "label": "PART-OF", "cpr": "1"}
{"text": "<< Carbonic anhydrase >> inhibitors: [[ aromatic and heterocyclic sulfonamides ]] incorporating adamantyl moieties with strong anticonvulsant activity.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "<< Carbonic anhydrase >> inhibitors: aromatic and heterocyclic sulfonamides incorporating [[ adamantyl ]] moieties with strong anticonvulsant activity.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Some of these derivatives showed good inhibitory potency against two << human CA >> isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs [[ acetazolamide ]] and methazolamide.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, << CA I >>, and CA II, of the same order of magnitude as the clinically used drugs [[ acetazolamide ]] and methazolamide.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and << CA II >>, of the same order of magnitude as the clinically used drugs [[ acetazolamide ]] and methazolamide.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Some of these derivatives showed good inhibitory potency against two << human CA >> isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and [[ methazolamide ]].", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, << CA I >>, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and [[ methazolamide ]].", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and << CA II >>, of the same order of magnitude as the clinically used drugs acetazolamide and [[ methazolamide ]].", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Perinatal exposure to << BDE-99 >> causes learning disorders and decreases serum thyroid hormone levels and [[ BDNF ]] gene expression in hippocampus in rat offspring.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "Development of potent and selective << indomethacin >> analogues for the inhibition of [[ AKR1C3 ]] (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Development of potent and selective << indomethacin >> analogues for the inhibition of AKR1C3 ([[ Type 5 17β-hydroxysteroid dehydrogenase ]]/prostaglandin F synthase) in castrate-resistant prostate cancer.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Development of potent and selective << indomethacin >> analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/[[ prostaglandin F synthase ]]) in castrate-resistant prostate cancer.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "<< AKR1C3 >> is upregulated in CRPC where it catalyzes the formation of potent [[ androgens ]].", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "<< Indomethacin >>, used to inhibit [[ cyclooxygenase ]], also inhibits AKR1C3 and displays selectivity over AKR1C1/AKR1C2.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "<< Indomethacin >>, used to inhibit cyclooxygenase, also inhibits [[ AKR1C3 ]] and displays selectivity over AKR1C1/AKR1C2.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Parallel synthetic strategies were used to generate libraries of << indomethacin >> analogues, which exhibit reduced [[ cyclooxygenase ]] inhibitory activity but retain AKR1C3 inhibitory potency and selectivity.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Parallel synthetic strategies were used to generate libraries of << indomethacin >> analogues, which exhibit reduced cyclooxygenase inhibitory activity but retain [[ AKR1C3 ]] inhibitory potency and selectivity.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "The << AKR1C3 >>·[[ NADP(+) ]]·2'-des-methyl-indomethacin crystal structure was determined, and it revealed a unique inhibitor binding mode.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The << AKR1C3 >>·NADP(+)·[[ 2'-des-methyl-indomethacin ]] crystal structure was determined, and it revealed a unique inhibitor binding mode.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "CRPC is characterized by reactivation of the << androgen >> axis due to changes in [[ androgen receptor ]] signaling and/or adaptive intratumoral androgen biosynthesis.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "CRPC is characterized by reactivation of the androgen axis due to changes in << androgen receptor >> signaling and/or adaptive intratumoral [[ androgen ]] biosynthesis.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "<< Indomethacin >>, used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over [[ AKR1C1 ]]/AKR1C2.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "<< Indomethacin >>, used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over AKR1C1/[[ AKR1C2 ]].", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "PURPOSE: The << fluoropyrimidine carbamate >> (capecitabine) is converted to 5-fluorouracil (5-FU) by [[ thymidine phosphorylase ]] (TP) inside target tissues.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "PURPOSE: The fluoropyrimidine carbamate (<< capecitabine >>) is converted to 5-fluorouracil (5-FU) by [[ thymidine phosphorylase ]] (TP) inside target tissues.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "PURPOSE: The << fluoropyrimidine carbamate >> (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ([[ TP ]]) inside target tissues.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "PURPOSE: The fluoropyrimidine carbamate (<< capecitabine >>) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ([[ TP ]]) inside target tissues.", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to << 5-fluorouracil >> (5-FU) by [[ thymidine phosphorylase ]] (TP) inside target tissues.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (<< 5-FU >>) by [[ thymidine phosphorylase ]] (TP) inside target tissues.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to << 5-fluorouracil >> (5-FU) by thymidine phosphorylase ([[ TP ]]) inside target tissues.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (<< 5-FU >>) by thymidine phosphorylase ([[ TP ]]) inside target tissues.", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "<< 5-FU >> interferes with DNA synthesis by blocking [[ thymidylate synthase ]] (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD).", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "<< 5-FU >> interferes with DNA synthesis by blocking thymidylate synthase ([[ TS ]]) but is inactivated by dihydropyrimidine dehydrogenase (DPD).", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "<< 5-FU >> interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by [[ dihydropyrimidine dehydrogenase ]] (DPD).", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "<< 5-FU >> interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase ([[ DPD ]]).", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "The specificity of << progestagens >> for the [[ progesterone receptors ]] in the cytosol fraction of MCF-7 cells was similar to that for progesterone receptors in human and rabbit myometrial cytosol but different from that for the progesterone receptor in rat myometrial cytosol.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The specificity of << progestagens >> for the progesterone receptors in the cytosol fraction of MCF-7 cells was similar to that for [[ progesterone receptors ]] in human and rabbit myometrial cytosol but different from that for the progesterone receptor in rat myometrial cytosol.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The specificity of << progestagens >> for the progesterone receptors in the cytosol fraction of MCF-7 cells was similar to that for progesterone receptors in human and rabbit myometrial cytosol but different from that for the [[ progesterone receptor ]] in rat myometrial cytosol.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of << 3-keto-desogestrel >>, the major metabolite of desogestrel, for the [[ progesterone receptor ]] in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the << progesterone receptor >> in intact MCF-7 cells was twice that of [[ levonorgestrel ]] and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the << progesterone receptor >> in intact MCF-7 cells was twice that of levonorgestrel and [[ Org 2058 ]], three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the << progesterone receptor >> in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of [[ medroxy-progesterone acetate ]] (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the << progesterone receptor >> in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate ([[ MPA ]]), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the << progesterone receptor >> in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of [[ norethisterone ]] and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the << progesterone receptor >> in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of [[ progesterone ]] and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the << progesterone receptor >> in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and [[ cyproterone acetate ]] whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the << progesterone receptor >> in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) [[ 3-keto-desogestrel ]] and Org 2058 displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the << progesterone receptor >> in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and [[ Org 2058 ]] displayed similar affinity.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The stronger binding of << 3-keto-desogestrel >> in intact cells was due to the higher stability of its complex with the [[ progesterone receptor ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of << 3-keto-desogestrel >> for the [[ androgen receptor ]] in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and medroxyprogesterone acetate (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the << androgen receptor >> in intact MCF-7 cells was half that of [[ levonorgestrel ]], similar to that of norethisterone and medroxyprogesterone acetate (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the << androgen receptor >> in intact MCF-7 cells was half that of levonorgestrel, similar to that of [[ norethisterone ]] and medroxyprogesterone acetate (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the << androgen receptor >> in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and [[ medroxyprogesterone acetate ]] (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the << androgen receptor >> in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and medroxyprogesterone acetate ([[ MPA ]]) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the << androgen receptor >> in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and medroxyprogesterone acetate (MPA) and at least three times higher than that of [[ progestagens ]] with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the << androgen receptor >> in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and medroxyprogesterone acetate (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of [[ progestagens ]] with androgenic and anti-androgenic properties.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "Of the progestagens tested in this study, only << norethinodrel >> displayed measurable but very low relative affinity for the [[ oestrogen receptor ]] in MCF-7 cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "Of the << progestagens >> tested in this study, only norethinodrel displayed measurable but very low relative affinity for the [[ oestrogen receptor ]] in MCF-7 cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "<< AMP-activated protein kinase >>-dependent and -independent mechanisms underlying in vitro antiglioma action of [[ compound C ]].", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "We investigated the effect of << compound C >>, a well-known inhibitor of the intracellular energy sensor [[ AMP-activated protein kinase ]] (AMPK), on proliferation and viability of human U251 and rat C6 glioma cell lines.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "We investigated the effect of << compound C >>, a well-known inhibitor of the intracellular energy sensor AMP-activated protein kinase ([[ AMPK ]]), on proliferation and viability of human U251 and rat C6 glioma cell lines.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "<< Compound C >> caused G(2)/M cell cycle block, accompanied by apoptotic glioma cell death characterized by [[ caspase ]] activation, phosphatidylserine exposure and DNA fragmentation.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "The mechanisms underlying the pro-apoptotic action of << compound C >> involved induction of oxidative stress and downregulation of antiapoptotic molecule [[ Bcl-2 ]], while no alteration of pro-apoptotic Bax was observed.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "The mechanisms underlying the pro-apoptotic action of << compound C >> involved induction of oxidative stress and downregulation of antiapoptotic molecule Bcl-2, while no alteration of pro-apoptotic [[ Bax ]] was observed.", "metadata": [], "label": "NOT", "cpr": "10"}
{"text": "<< Compound C >> diminished AMPK phosphorylation and enzymatic activity, resulting in reduced phosphorylation of its target [[ acetyl CoA carboxylase ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "<< AMPK >> activators [[ metformin ]] and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of human AMPK mimicked compound C-induced G(2)/M cell cycle arrest, but failed to induce oxidative stress and apoptosis in U251 glioma cells.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "<< AMPK >> activators metformin and [[ AICAR ]] partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of human AMPK mimicked compound C-induced G(2)/M cell cycle arrest, but failed to induce oxidative stress and apoptosis in U251 glioma cells.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "In conclusion, our data indicate that << AMPK >> inhibition is required, but not sufficient for [[ compound C ]]-mediated apoptotic death of glioma cells.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "<< Compound C >> diminished [[ AMPK ]] phosphorylation and enzymatic activity, resulting in reduced phosphorylation of its target acetyl CoA carboxylase.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "<< Dimethylarginine dimethylaminohydrolase 1 >> (DDAH1) is an enzyme that metabolizes [[ methylated arginine ]] to citrulline and methylamine, thus working to produce nitric oxide (NO).", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Dimethylarginine dimethylaminohydrolase 1 (<< DDAH1 >>) is an enzyme that metabolizes [[ methylated arginine ]] to citrulline and methylamine, thus working to produce nitric oxide (NO).", "metadata": [], "label": "SUBSTRATE", "cpr": "9"}
{"text": "Dimethylarginine dimethylaminohydrolase 1 (<< DDAH1 >>) is an enzyme that metabolizes methylated arginine to [[ citrulline ]] and methylamine, thus working to produce nitric oxide (NO).", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "<< Dimethylarginine dimethylaminohydrolase 1 >> (DDAH1) is an enzyme that metabolizes methylated arginine to [[ citrulline ]] and methylamine, thus working to produce nitric oxide (NO).", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "<< Dimethylarginine dimethylaminohydrolase 1 >> (DDAH1) is an enzyme that metabolizes methylated arginine to citrulline and [[ methylamine ]], thus working to produce nitric oxide (NO).", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "Dimethylarginine dimethylaminohydrolase 1 (<< DDAH1 >>) is an enzyme that metabolizes methylated arginine to citrulline and [[ methylamine ]], thus working to produce nitric oxide (NO).", "metadata": [], "label": "PRODUCT-OF", "cpr": "9"}
{"text": "In patients who do not reach the << LDL >>-C target, combination therapy with additional LDL-C lowering drugs (e.g.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "In patients who do not reach the << LDL >>-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, [[ bile acid ]] sequestrants or fibrates) should be considered.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "In patients who do not reach the << LDL >>-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or [[ fibrates ]]) should be considered.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "In patients who do not reach the LDL-C target, combination therapy with additional << LDL >>-C lowering drugs (e.g.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "In patients who do not reach the LDL-C target, combination therapy with additional << LDL >>-C lowering drugs (e.g. ezetimibe, [[ bile acid ]] sequestrants or fibrates) should be considered.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "In patients who do not reach the LDL-C target, combination therapy with additional << LDL >>-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or [[ fibrates ]]) should be considered.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "<< SB225002 >> (SB) is an [[ IL-8 receptor B ]] (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "<< SB225002 >> (SB) is an IL-8 receptor B ([[ IL-8RB ]]) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "Molecular docking studies suggested that SB has a good affinity towards << vinblastine >>-binding site on [[ β-tubulin ]] subunit.", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "Of note, << SB265610 >> which is a close structural analogue of SB225002 with a potent [[ IL-8RB ]] antagonistic activity did not exhibit a similar antimitotic activity.", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "<< SB225002 >> (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit [[ IL-8 ]]-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Both the phosphotriesterase and << physostigmine >> treatments protected the brain [[ AChE ]] activities measured 24 h after sarin exposure.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher << sarin >> dose, respectively, was needed to cause a 50% inhibition of brain [[ AChE ]] activity.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "In phosphotriesterase and << physostigmine >>-treated mice, a 4- and 2-fold higher sarin dose, respectively, was needed to cause a 50% inhibition of brain [[ AChE ]] activity.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "The acute toxicity of organophosphorus (<< OP >>) compounds in mammals is due to their irreversible inhibition of [[ acetylcholinesterase ]] (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "The acute toxicity of organophosphorus (<< OP >>) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ([[ AChE ]]) in the nervous system, which leads to increased synaptic acetylcholine levels.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "The acute toxicity of << organophosphorus >> (OP) compounds in mammals is due to their irreversible inhibition of [[ acetylcholinesterase ]] (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "The acute toxicity of << organophosphorus >> (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ([[ AChE ]]) in the nervous system, which leads to increased synaptic acetylcholine levels.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "Both the phosphotriesterase and physostigmine treatments protected the brain << AChE >> activities measured 24 h after [[ sarin ]] exposure.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "We previously demonstrated that developmental exposure to a mixture of << polychlorinated biphenyls >> (PCBs) which was reconstituted according to the congener pattern found in human breast milk caused feminization of sweet preference as a sexually dimorphic behavior in adult male rats, following decreases in [[ aromatase ]] activity in the brain of newborn male pups.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "We previously demonstrated that developmental exposure to a mixture of polychlorinated biphenyls (<< PCBs >>) which was reconstituted according to the congener pattern found in human breast milk caused feminization of sweet preference as a sexually dimorphic behavior in adult male rats, following decreases in [[ aromatase ]] activity in the brain of newborn male pups.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "<< Rg1 >> attenuated the [[ Aβ25-35 ]]-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "<< Rg1 >> attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting [[ HIF-1α ]] expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cpr": "4"}
{"text": "These protective effects were abolished by << glucocorticoid receptor >> (GR) antagonist [[ RU486 ]] or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780.", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "These protective effects were abolished by glucocorticoid receptor (<< GR >>) antagonist [[ RU486 ]] or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780.", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or << p-ERK >> inhibitor [[ U0126 ]] rather than estrogen receptor α antagonist ICI 82,780.", "metadata": [], "label": "INHIBITOR", "cpr": "4"}
{"text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than << estrogen receptor α >> antagonist [[ ICI 82,780 ]].", "metadata": [], "label": "ANTAGONIST", "cpr": "6"}
{"text": "Taken together, our results suggested that << Rg1 >> protected against Aβ25-35-induced apoptosis at least in part by two complementary [[ GR ]]-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Taken together, our results suggested that << Rg1 >> protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent [[ ERK ]] phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "Taken together, our results suggested that << Rg1 >> protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating [[ HIF-1α ]] initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "These data provided a novel insight to the mechanisms of << Rg1 >>protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that [[ GR ]]-ERK signaling pathway might play an important role in it.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "These data provided a novel insight to the mechanisms of << Rg1 >>protective effects on Aβ25-35-induced endothelial cells apoptosis, suggesting that GR-[[ ERK ]] signaling pathway might play an important role in it.", "metadata": [], "label": "REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high << 5HT-2A >> affinity--[[ clozapine ]], olanzapine, risperidone vs. low 5HT-2A affinity--quetiapine, amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high << 5HT-2A >> affinity--clozapine, [[ olanzapine ]], risperidone vs. low 5HT-2A affinity--quetiapine, amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high << 5HT-2A >> affinity--clozapine, olanzapine, [[ risperidone ]] vs. low 5HT-2A affinity--quetiapine, amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, risperidone vs. low << 5HT-2A >> affinity--[[ quetiapine ]], amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, risperidone vs. low << 5HT-2A >> affinity--quetiapine, [[ amisulpride ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--<< clozapine >>, olanzapine, risperidone vs. low [[ 5HT-2A ]] affinity--quetiapine, amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--clozapine, << olanzapine >>, risperidone vs. low [[ 5HT-2A ]] affinity--quetiapine, amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, << risperidone >> vs. low [[ 5HT-2A ]] affinity--quetiapine, amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high << 5HT-2A >> affinity--clozapine, olanzapine, risperidone vs. low 5HT-2A affinity--[[ quetiapine ]], amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high << 5HT-2A >> affinity--clozapine, olanzapine, risperidone vs. low 5HT-2A affinity--quetiapine, [[ amisulpride ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the << 5HT-2A >> affinity of the individual medications (high 5HT-2A affinity--[[ clozapine ]], olanzapine, risperidone vs. low 5HT-2A affinity--quetiapine, amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the << 5HT-2A >> affinity of the individual medications (high 5HT-2A affinity--clozapine, [[ olanzapine ]], risperidone vs. low 5HT-2A affinity--quetiapine, amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the << 5HT-2A >> affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, [[ risperidone ]] vs. low 5HT-2A affinity--quetiapine, amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the << 5HT-2A >> affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, risperidone vs. low 5HT-2A affinity--[[ quetiapine ]], amisulpride).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "The patients were divided into two groups according to the << 5HT-2A >> affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, risperidone vs. low 5HT-2A affinity--quetiapine, [[ amisulpride ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cpr": "2"}
{"text": "Acute << arsenic >> treatment alters [[ cytochrome P450 ]] expression and arachidonic acid metabolism in lung, liver and kidney of C57Bl/6 mice.", "metadata": [], "label": "INDIRECT-REGULATOR", "cpr": "2"}
{"text": "Our results demonstrated that acute << As(III) >> treatment (12.5 mg/kg) altered [[ CYP ]] epoxygenases, CYP ω-hydroxylases and EPHX2 mRNA levels that were isozyme and tissue specific.", "metadata": [], "label": "INDIRECT-REGULATOR", "cpr": "2"}
{"text": "Our results demonstrated that acute << As(III) >> treatment (12.5 mg/kg) altered CYP [[ epoxygenases ]], CYP ω-hydroxylases and EPHX2 mRNA levels that were isozyme and tissue specific.", "metadata": [], "label": "INDIRECT-REGULATOR", "cpr": "2"}
{"text": "Our results demonstrated that acute << As(III) >> treatment (12.5 mg/kg) altered CYP epoxygenases, [[ CYP ]] ω-hydroxylases and EPHX2 mRNA levels that were isozyme and tissue specific.", "metadata": [], "label": "INDIRECT-REGULATOR", "cpr": "2"}
{"text": "Our results demonstrated that acute << As(III) >> treatment (12.5 mg/kg) altered CYP epoxygenases, CYP [[ ω-hydroxylases ]] and EPHX2 mRNA levels that were isozyme and tissue specific.", "metadata": [], "label": "INDIRECT-REGULATOR", "cpr": "2"}
{"text": "Our results demonstrated that acute << As(III) >> treatment (12.5 mg/kg) altered CYP epoxygenases, CYP ω-hydroxylases and [[ EPHX2 ]] mRNA levels that were isozyme and tissue specific.", "metadata": [], "label": "INDIRECT-REGULATOR", "cpr": "2"}
{"text": "<< As(III) >> also increased total [[ epoxygenases ]] activity in the lung while it decreased its levels in the kidney and had no effect on the liver.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "Lastly, << As(III) >> increased [[ soluble epoxide hydrolase ]] activity in the lung, while it decreased its levels in the kidney and had no effect on the liver.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
{"text": "<< MNU >>-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of [[ E-cadherin ]], and high MGMT staining.", "metadata": [], "label": "DOWNREGULATOR", "cpr": "4"}
{"text": "<< MNU >>-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high [[ MGMT ]] staining.", "metadata": [], "label": "UPREGULATOR", "cpr": "3"}
